Coeptis Secures Five New Clients With Total Contract Value of
$1.7 Million Dollars With More On The
Horizon Signaling AI-Driven Marketing Innovations in Biopharma for
Coeptis
WEXFORD,
Pa., Jan. 7, 2025 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or
"Coeptis"), a biopharmaceutical company focused on pioneering cell
therapy platforms for cancer, autoimmune, and infectious diseases,
is excited to announce the initial rollout of its recently
introduced NexGenAI Affiliates Network platform. With five new
customers already signed on to leverage the platform's cutting-edge
AI-driven marketing solutions, Coeptis believes it can bolster its
operational landscape and amplify revenue growth prospects.
The signing of multiple Managed Services Agreements, valued at
$1.25 million dollars and an
anticipated revenue stream of $450,000 supporting recurring monthly cash
revenues, in addition to any new revenues generated from additional
contracts with prospective clients, underscores Coeptis' view of
the immediate market opportunity for its NexGenAI Affiliates
Network platform and innovative technology.
Dave Mehalick, President and CEO
of Coeptis, stated, "We are pleased to see an enthusiastic uptake
of our NexGenAI marketing platform. This early engagement
highlights the power of AI-driven capabilities while supporting our
vision to innovate and lead in highly competitive sectors. We are
focused on a rapid rollout of our platform throughout 2025, to
create opportunities for enhanced customer engagement and
supporting improved marketing strategies."
As Coeptis Therapeutics continues expanding its business plan,
the early traction of the NexGenAI marketing platform reinforces
the commitment of Coeptis to deliver exceptional value in the
biopharmaceutical sector and pioneering technology in the marketing
landscape. Coeptis is dedicated to unlocking the full potential of
AI in marketing and solidifying its position as a forward-thinking
leader in biopharmaceutical advancements.
Artificial Intelligence is transforming the marketing industry
and has the potential to significantly impact the broader economy.
Through advanced algorithms and data analytics, AI marketing
platforms enable businesses to enhance personalization, optimize
campaigns in real time, and gain valuable insights into consumer
behavior. This technology is improving operational efficiencies and
facilitating innovative strategies for consumer engagement. As AI
continues to evolve, it is expected to play a crucial role in
shaping various sectors and driving advancements in both business
practices and daily life.
Mr. Mehalick went on to say "We expect the integration of these
AI-powered tools by Coeptis to allow us to elevate our revenue
growth and marketing processes and to enhance relationships with
existing and prospective customers. As Coeptis continues its
focus on innovation and expansion, we are encouraged by the early
traction of our NexGenAI Affiliates Network platform and excited to
build on such early success in our effort to deliver exceptional
value to the biopharmaceutical sector. While this represents
initial growth, we foresee this figure multiplying significantly as
we engage in additional contracts with prospective clients that we
are currently in discussions with, reinforcing our strategic
intention to expand and solidify our foothold in the market. Our
recent achievements mark just the beginning of a promising growth
path as we work tirelessly to secure multiple contracts with
numerous organizations and drive exceptional value for our
shareholders."
About Coeptis Therapeutics Holdings, Inc.:
Coeptis Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics, Inc. and Coeptis
Pharmaceuticals, Inc., (collectively "Coeptis"), is a
biopharmaceutical company developing innovative cell therapy
platforms for cancer, autoimmune, and infectious diseases that have
the potential to disrupt conventional treatment paradigms and
improve patient outcomes. Coeptis' product portfolio is highlighted
by assets licensed from Deverra Therapeutics, including an
allogeneic cellular immunotherapy platform and DVX201, a
clinical-stage, unmodified natural killer cell therapy technology.
Additionally, Coeptis is developing a universal, multi-antigen CAR
T technology licensed from the University of
Pittsburgh (SNAP-CAR), and the GEAR cell therapy and
companion diagnostic platforms in collaboration with VyGen-Bio and
leading medical researchers at the Karolinska
Institute. The Company is headquartered in Wexford, PA. For more information on Coeptis
visit [https://coeptistx.com/](https://coeptistx.com/).
About NexGenAI Affiliates Network:
NexGenAI Affiliates Network is powered by a proprietary suite of
advanced technologies designed to revolutionize marketing and
business operations. Our cutting-edge platform integrates AI-driven
marketing software, robotic process automation (RPA), and
actionable data analytics to optimize campaigns, streamline
operations, and deliver unparalleled insights. By leveraging
artificial intelligence, we can empower businesses across various
sectors to automate processes, enhance communication strategies,
and drive sustainable growth.
To further expand its capabilities, the NexGenAI platform
introduces innovative features such as an AI Dialer Service for
seamless customer outreach, an AI SMS Service for optimized
communication, and advanced RPA Assistance for next-generation
human-machine interfaces in marketing, recruitment, investment, and
affiliate services. These upcoming additions aim to build upon
existing technologies, delivering even greater value to businesses
seeking innovative and efficient solutions for their operations.
For more information, visit nexgenaiaffiliates.io.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the risk that the integration of the Deverra
licensed assets will disrupt current plans and operations of the
Company; (3) the inability to recognize the anticipated benefits of
the newly-licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (4) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (5) costs related to integrating the
newly-licensed Deverra assets and pursuing the contemplated asset
development paths; (6) changes in applicable laws or regulations;
(7) the possibility that the Company may be adversely affected by
other economic, business, and/or competitive factors; and (8) the
impact of the global COVID-19 pandemic on any of the foregoing
risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC").
The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks
including, but not limited, to those risks contained or to be
contained in reports and other filings filed by the Company with
the SEC. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings made or to be made with the SEC, which are
available for review at www.sec.gov. We undertake no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof unless required
by applicable laws, regulations, or rules.
Contacts
For Coeptis Therapeutics, Inc.:
IR@coeptistx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-announces-first-customer-adoptions-of-its-nexgenai-marketing-platform-302343731.html
SOURCE Coeptis Pharmaceuticals, Inc.